Open Access

Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis

  • Authors:
    • Hong Liu
    • Ligang Zhang
    • Pengyan Wang
  • View Affiliations

  • Published online on: July 23, 2019     https://doi.org/10.3892/mmr.2019.10514
  • Pages: 2694-2702
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Complement factor H‑related 3 (CFHR3) belongs to the human factor H protein family and is associated with various human diseases, including nephropathy, age‑related macular degeneration and atypical hemolytic uremic syndrome. However, to the best of our knowledge, the role of CFHR3 in hepatocellular carcinoma (HCC) remains largely unknown. In the present study, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis were performed to determine mRNA and protein expression levels of CFHR3 in HCC and normal adjacent tissue. In addition, CFHR3 was overexpressed in Huh‑7 cells and cell counting kit‑8 assay was used to determine cell viability. Cell proliferation and apoptosis were assessed using flow cytometry, RT‑qPCR and western blotting. The results demonstrated that mRNA (2‑ΔΔCq) and protein expression levels of CFHR3 were significantly lower in tumor tissue compared with in adjacent tissue. Additionally, CFHR3 overexpression decreased cell viability, inhibited cell proliferation and significantly increased apoptosis. It was also identified that CFHR3 could downregulate the expression of Ki67. The results suggested that CFHR3 induced apoptosis by downregulating the expression of survivin and B cell lymphoma 2, upregulating the expression of Bcl‑2‑associated X and promoting caspase‑3 activity. Western blotting revealed that CFHR3 significantly inhibited the protein expression levels of phosphorylated (p)‑phosphoinositide 3‑kinase (PI3K), p‑protein kinase B (Akt) and p‑mammalian target of rapamycin (mTOR). Overexpression of CFHR3 suppressed proliferation and promoted apoptosis of HCC cells by inhibiting the PI3K/Akt/mTOR signaling pathway.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

European Association For The Study Of The Liver; European Organisation For Research and Treatment Of Cancer, . EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Chan SL, Wong AM, Lee K, Wong N and Chan AK: Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treat Rev. 45:77–86. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Liu J and Fan D: Hepatitis B in China. Lancet. 369:1582–1583. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Mohd Hanafiah K, Groeger J, Flaxman AD and Wiersma ST: Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 57:1333–1342. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Sartorius K, Sartorius B, Aldous C, Govender PS and Madiba TE: Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 39:284–290. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, et al: Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 13:397–406. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, Brade V, Kraiczy P, Noris M and Remuzzi G: Factor H family proteins: On complement, microbes and human diseases. Biochem Soc Trans. 30:971–978. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S and Zipfel PF: Functional properties of complement factor H-related proteins FHR-3 and FHR-4: Binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 462:345–352. 1999. View Article : Google Scholar : PubMed/NCBI

10 

McRae JL, Duthy TG, Griggs KM, Ormsby RJ, Cowan PJ, Cromer BA, McKinstry WJ, Parker MW, Murphy BF and Gordon DL: Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 174:6250–6256. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Kotarsky H, Hellwage J, Johnsson E, Skerka C, Svensson HG, Lindahl G, Sjobring U and Zipfel PF: Identification of a domain in human factor H and factor H-like protein-1 required for the interaction with streptococcal M proteins. J Immunol. 160:3349–3354. 1998.PubMed/NCBI

12 

Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, et al: Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol. 16:1392–1403. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, et al: Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 3:e4312006. View Article : Google Scholar : PubMed/NCBI

14 

Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, et al: Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3:e412007. View Article : Google Scholar : PubMed/NCBI

15 

Monteferrante G, Brioschi S, Caprioli J, Pianetti G, Bettinaglio P, Bresin E, Remuzzi G and Noris M: Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol. 44:1704–1708. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T and Chakravarthy U: A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 38:1173–1177. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, et al: Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution and evolutionary implications. Ann Med. 38:592–604. 2006. View Article : Google Scholar :

18 

Kavanagh D, Richards A and Atkinson J: Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 59:293–309. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, Williams L, Enfield D and Hass GM: Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 4:2511–2520. 1998.PubMed/NCBI

20 

Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF and Meri S: Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol. 164:6075–6081. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Corey MJ, Kinders RJ, Poduje CM, Bruce CL, Rowley H, Brown LG, Hass GM and Vessella RL: Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis. J Biol Chem. 275:12917–12925. 2000. View Article : Google Scholar : PubMed/NCBI

22 

Fedarko NS, Fohr B, Robey PG, Young MF and Fisher LW: Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem. 275:16666–16672. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Jozsi M, Manuelian T, Heinen S, Oppermann M and Zipfel PF: Attachment of the soluble complement regulator factor H to cell and tissue surfaces: Relevance for pathology. Histol Histopathol. 19:251–258. 2004.PubMed/NCBI

24 

Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 7:4060–4066. 2001.PubMed/NCBI

25 

Cui L, Fu J, Pang JC, Qiu ZK, Liu XM, Chen FR, Shi HL, Ng HK and Chen ZP: Overexpression of IL-7 enhances cisplatin resistance in glioma. Cancer Biol Ther. 13:496–503. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Sabatini DM: mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer. 6:729–734. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J and Brú C: Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 101:72–81. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

29 

Hoefel D, Grooby WL, Monis PT, Andrews S and Saint CP: A comparative study of carboxyfluorescein diacetate and carboxyfluorescein diacetate succinimidyl ester as indicators of bacterial activity. J Microbiol Methods. 52:379–388. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, et al: Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 43:321–327. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Munch J, Bachmann A, Grohmann M, Mayer C, Kirschfink M, Lindner TH, Bergmann C and Halbritter J: Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies. Clin Kidney J. 10:742–746. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Bakri NM, Ramachandran V, Kee HF, Subrayan V, Isa H, Ngah NF, Mohamad NA, Mooi CS, Mun CY, Ismail P, et al: Association of copy number variations in complement factor H-Related genes among age-related macular degenerative subjects. Kaohsiung J Med Sci. 33:602–608. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjorge L, Butzow R, Zipfel PF and Meri S: Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer. 87:1119–1127. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Khan FH, Pandian V, Ramraj S, Natarajan M, Aravindan S, Herman TS and Aravindan N: Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes. BMC Cancer. 15:5142015. View Article : Google Scholar : PubMed/NCBI

35 

Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W and Amano J: Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 191:381–388. 2000. View Article : Google Scholar : PubMed/NCBI

36 

Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM and Wong J: Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg. 234:63–70. 2001. View Article : Google Scholar : PubMed/NCBI

37 

Bosch J and Forns X: Therapy. Statins and liver disease: From concern to ‘wonder’ drugs? Nat Rev Gastroenterol Hepatol. 12:320–321. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Zhang H, Gao C, Fang L, Zhao HC and Yao SK: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: A meta-analysis. Scand J Gastroenterol. 48:78–87. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Forones NM, Carvalho AP, Giannotti-Filho O, Lourenço LG and Oshima CT: Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterol. 42:30–44. 2005. View Article : Google Scholar : PubMed/NCBI

40 

Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI

41 

Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI

42 

Choudhary GS, Al-Harbi S and Almasan A: Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol. 1219:1–9. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, et al: Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 51:725–733. 2009. View Article : Google Scholar : PubMed/NCBI

44 

Villanueva A, Toffanin S and Llovet JM: Linking molecular classification of hepatocellular carcinoma and personalized medicine: Preliminary steps. Curr Opin Oncol. 20:444–453. 2008. View Article : Google Scholar : PubMed/NCBI

45 

Wang J, Ouyang C, Chen X, Fu B, Lu Y and Hong Q: Effect of Jak2 kinase inhibition on Stat1 and Stat3 activation and apoptosis of tubular epithelial cells induced by ATP depletion/recovery. J Nephrol. 21:919–923. 2008.PubMed/NCBI

46 

Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Rohrs S, Romani J, Scherr M, Zaborski M and Drexler HG: SOCS2: Inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 22:2169–2175. 2008. View Article : Google Scholar : PubMed/NCBI

47 

Herbst A and Kolligs FT: Wnt signaling as a therapeutic target for cancer. Methods Mol Biol. 361:63–91. 2007.PubMed/NCBI

48 

Yang J, Pi C and Wang G: Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 103:699–707. 2018. View Article : Google Scholar : PubMed/NCBI

49 

Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J and Ge C: A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther. 10:2115–2126. 2017. View Article : Google Scholar : PubMed/NCBI

50 

Wang X, Zeng J, Wang L, Zhang X, Liu Z, Zhang H and Dong J: Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway. Oncol Rep. 38:141–150. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, H., Zhang, L., & Wang, P. (2019). Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis. Molecular Medicine Reports, 20, 2694-2702. https://doi.org/10.3892/mmr.2019.10514
MLA
Liu, H., Zhang, L., Wang, P."Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis". Molecular Medicine Reports 20.3 (2019): 2694-2702.
Chicago
Liu, H., Zhang, L., Wang, P."Complement factor H‑related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis". Molecular Medicine Reports 20, no. 3 (2019): 2694-2702. https://doi.org/10.3892/mmr.2019.10514